Review top news and interview highlights from the week ending May 6, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Enrollment is ongoing in the phase 1 CEDAR trial, which plans to dose the first patient later in 2022.
Rami Elghandour, chairman and CEO of Arcellx, shares updates on the phase 1 trial of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
New data from cohort 4 showed outer retinal restoration following treatment with OpRegen.
The CEO and managing director of Chimeric Therapeutics hopes to contribute to the narrative with a handful of offerings in development across 2 platforms: CORE-NK, which uses allogeneic natural killer cells, and T-cell derived autologous therapies.
The post-hoc analysis of the OPTIC trial explored the effects of neutralizing antibodies on patients treated with ADVM-002.